If MYL gets approval for generic Advair (as it says it will) and the LAMA compound licensed from PFE pans out, MYL will be competing at both ends of the respiratory arena.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.